Fram G

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.

5 papers · 1 preprint

ArticlePsilocybin

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.

Agin-Liebes G, Shnayder S, Fram G +6

Europe PMC2026
ArticleKetamine

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Wilkinson ST, Prashad S, Dalthorp R +10

Europe PMC2026
PreprintPsilocybin

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

Kelmendi B, Adams T, Ching THW +16

Europe PMC2026
ArticlePsilocybin

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.

Ching THW, Stahnke B, Shnayder S +22

Europe PMC2025
ArticlePsilocybin

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +16

Europe PMC2024
ArticlePsilocybin

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +15

Europe PMC2023